{"id":"NCT04561115","sponsor":"Grifols Therapeutics LLC","briefTitle":"A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency","officialTitle":"A Phase 3, Multicenter, Open-label, Single-sequence, Cross-over, Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of IVIG-PEG Compared to Gamunex-C in Subjects With Primary Humoral Immunodeficiency","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-09-02","primaryCompletion":"2022-03-28","completion":"2022-03-28","firstPosted":"2020-09-23","resultsPosted":"2023-06-05","lastUpdate":"2023-06-05"},"enrollment":33,"design":{"allocation":"NON_RANDOMIZED","model":"SEQUENTIAL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Primary Immunodeficiency"],"interventions":[{"type":"BIOLOGICAL","name":"Gamunex-C","otherNames":["IVIG-C"]},{"type":"BIOLOGICAL","name":"IVIG-PEG","otherNames":[]}],"arms":[{"label":"Gamunex-C","type":"ACTIVE_COMPARATOR"},{"label":"IVIG-PEG","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to demonstrate bioequivalence of IVIG-PEG with Gamunex-C (IVIG-C) at steady-state as determined by comparing total Immunoglobulin G (IgG) area under the concentration-time curve during the defined dosing interval (\\[AUC0-Ï„\\] either every 3 weeks \\[AUC0-21 days\\] or every 4 weeks \\[AUC0-28 days\\]) and maximum concentration in a dosing interval (Cmax) in participants diagnosed with primary humoral immunodeficiency (PI) currently receiving chronic IVIG replacement treatment.","primaryOutcome":{"measure":"AUC (0-7): Area Under the Concentration Time Curve Over a Dosing Interval of Either Every 3 Weeks [AUC0-21 Days] or Every 4 Weeks [AUC0-28 Days] for Total Immunoglobulin G (IgG)","timeFrame":"Pre-dose, within 10 minutes of last infusion completion, at 1, 3, 6, 24, 48 hours and 4, 7, 14 and 21 days (up to 3 weeks), and 28 days (up to 4 weeks - only for subjects on a 4-week dosing schedule) post-infusion","effectByArm":[{"arm":"Gamunex-C","deltaMin":232088.8,"sd":32848.46},{"arm":"IVIG-PEG","deltaMin":219149.9,"sd":36894.29}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":19},"locations":{"siteCount":10,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":33},"commonTop":["Headache","Sinusitis","COVID-19","Diarrhoea","Upper Respiratory Tract Infection"]}}